Fig 1.
Patient disposition.
Fig 2.
RA = rheumatoid arthritis; PK = pharmacokinetics; DAS28 = Disease Activity Score based on a 28-joint count; CDAI = Clinical Disease Activity Index; SDAI = Simplified Disease Activity Index; VAS = visual analog scale; ESR = erythrocyte sedimentation rate; CRP = C-reactive protein; PRO = patient- reported outcome; HAQ-DI = health assessment questionnaire-disability index; EQ-5D = EuroQol-5 Dimensions; SF-36 = Short-Form Health Survey; AE = adverse event. * Argentina, Australia, Bulgaria, Turkey, USA.
Table 1.
Patient characteristics.
Fig 3.
Proportion of patients (A) with ADA by treatment, (B) achieving LDA by treatment and ADA status, (C) achieving remission by treatment and ADA status, and (D) mean drug concentration by treatment.
ADA = antidrug antibodies; LDA = low disease activity; ETN = etanercept; ADL = adalimumab; IFX = infliximab.
Fig 4.
Relationship between ADA status and ESR (A, C, and E) or CRP (D-F) by treatment: ETN (A, D), ADL (B, E), IFX (C, F).
Fig 5.
Mean total score by treatment and ADA status for (A) DAS28-ESR, (B) DAS28-CRP, (C) CDAI, and (D) SDAI.
ADA = antidrug antibodies; DAS28 = disease activity score based on a 28-joint count; ESR = erythrocyte sedimentation rate; CRP = C-reactive protein; CDAI = clinical disease activity index; SDAI = simplified disease activity index; ETN = etanercept; ADL = adalimumab; IFX = infliximab.
Fig 6.
Correlation between serum trough drug concentration and ESR (A, C, and E) or CRP (B, D, and F) by treatment: ETN (A, B), ADL (C, D), IFX (E, F).
Table 2.
Correlations of efficacy measures with ADA titers and serum trough drug concentrations.
Table 3.
Correlations of serum trough drug concentration with PROs.
Table 4.
Summary of adverse events and targeted medical history.